Agreement Lonza Expands Dual-Payload ADC Technology Offering Through Exclusive Access to Qurient’s CDK7 Inhibitors 12.10.2026 / 14:00 CET/CEST Basel, Switzerland and Seongnam, Korea, 12 October 2026 – ...
There are a variety of treatments available for IBS, including lifestyle changes, gut-directed mental health therapies, ...
Avacopan (Tavneos), the complement pathway inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis ...
A vote taken by the sound of applause rang out during an early morning session at (AAO) 2026 annual meeting, where 2 experts discussed the pros and cons of using complement inhibitors to treat ...
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the ...
The new lenacapavir/cabotegravir combo brought HIV under control within 13 weeks among patients with detectable levels, ...
An investigational antibody-drug conjugate demonstrated clinically meaningful and durable responses in patients with platinum-resistant ovarian cancer, including patients whose tumors had low or no ...
PRP is a proprietary intravenous fixed-ratio combination of the pancreatic proenzymes, trypsinogen and chymotrypsinogen (1:6). It does not inhibit RAS. In orthotopic and patient-derived xenograft ...
A new class of medicines offers steadier protection with fewer injections, while gene therapy is beginning to test the promise of a one-time treatment.
For the first time in a human trial, a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, already ...
Individuals taking the drug saw a significant drop in these inflammatory cell clumps within just two weeks, and the reduction grew even stronger by week 12.
Initial Phase 1b data highlight promising clinical activity in patients with PROC and support continued clinical development of CUSP06 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results